Nu Skin shares fell 8.9% after earnings, despite revenue and adjusted EPS landing within the company’s guidance range. The likely disappointment was continued pressure in the core business: customer and sales metrics remain under pressure, and management’s outlook for Q4 relies on anticipated sequential revenue growth rather than describing a recovery already underway.
Nu Skin’s shares dropped 11.3% following the quarter, reflecting investor disappointment primarily driven by cautious full-year guidance and ongoing challenges in sales force recruitment and leadership development, suggesting deceleration in core business momentum.
Nu Skin Enterprises reported Q3 2025 revenue of $364 million, aligning with guidance, and delivered an EPS of $0.34, reflecting robust performance amid macro challenges. The company is poised for growth with the upcoming introduction of its Prysm iO wellness platform and entry into the Indian market.